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Metastatic calciﬁcation is a frequent complication encountered in patients undergoing maintenance dialysis and has a complex
pathogenesis. It is often diﬃcult to treat and is associated with high morbidity and mortality. Early recognition and prompt
initiation of treatment is vital. Local wound care and aggressive metabolic control remain the cornerstones of the therapy. Various
novel treatment strategies including sodium thiosulfate and hyperbaric oxygen therapy have been utilized and reviewed in this
paper. The response rate to treatment is poor and prevention is the best approach.
1.Introduction
Extraskeletal metastatic calciﬁcations are seen frequently
in patients undergoing maintenance dialysis, and the inci-
dence increases with dialysis vintage [1]. Calciphylaxis is
a rare but life-threatening form, characterized by systemic
medial calciﬁcation of the arterioles leading to ischemia
and subcutaneous necrosis. It is reported to occur from
as little as 1 month to as long as 12 years after the onset
of end-stage renal disease (ESRD), with a median time of
2 years and 9 months [2]. The term “calciphylaxis” was
coined in 1962 by Hans Selye, who used it to describe
a systemic anaphylactic reaction leading to soft-tissue and
vascular calciﬁcation in animal models [3]. It continues to
be used widely to describe the phenomenon in humans,
despite the introduction of “calciﬁc uremic arteriolopathy”
(CUA) as a more descriptive term. The incidence of this
condition appears to be increasing, due in part to the use
of calcium-based phosphate binders and vitamin D analogs
forthetreatmentofseverehyperparathyroidism[4].Another
contributing factor is a greater awareness and recognition of
clinical signs and risk factors associated with calciphylaxis.
It is estimated to have an incidence of 1% per year [5]
and a prevalence of 4.1% in dialysis patients [1], with
preponderance among obese, Caucasian females [2, 5, 6]
and diabetic patients [7]. Reports to the Australian and
New Zealand Dialysis and Transplant Registry (ANZDATA)
identiﬁed calciphylaxis as a cause of death in 64 patients
(from 1985 until March 2004) and listed it as a comorbid
condition in 86 cases [8].
Slowly progressive metastatic calciﬁcations are much
more common than calciphylaxis in patients with end-stage
renal disease. Common sites of involvement are the blood
vessels, periarticular regions, heart, lungs, kidneys, gastric
mucosa, central nervous system, breasts, and eyes. The liver,
spleen, skeletal muscle, small and large bowel, peritoneal
cavity, tongue, and larynx are less commonly aﬀected [9].
2. Pathogenesis
The pathogenesis of calciphylaxis is complex and poorly
understood. Intimal ﬁbrosis, mural calciﬁcations of the der-
mohypodermic arterioles, and vascular thrombus formation
all reduce arteriolar blood ﬂow leading to microvascular
ischemia [10]. This results in areas of painful ischemic
necrosis in the dermis and subcutaneous fat, mainly involv-
ing the abdomen, buttocks, and medial aspects of the2 International Journal of Nephrology
Figure 1: A large, necrotic, nonhealing ulceration on the abdomen
of a patient with end stage renal disease, typical of a calciphylactic
lesion.
thighs. It manifests as livedo reticularis and/or violaceous,
painful, plaque-like subcutaneous nodules, which progress
to ischemic/necrotic ulcers with eschars that often become
superinfected (Figure 1). Less commonly involved organs
and muscle groups include kidneys, heart, skeletal mus-
cle, lungs, and gastrointestinal tract [11]. Abnormalities
in mineral metabolism including hyperphosphatemia [6],
hyperparathyroidism [12], an elevated plasma calcium and
phosphate product [13] and active vitamin D supple-
mentation [14] and deﬁciency of inhibitors of vascular
calciﬁcations, such as fetuin-A [15, 16] and matrix Gla
protein [17], have all been implicated in this process. High
level of 1,25-dihydroxy vitamin D3 has been associated with
deleterious eﬀect on the vascular smooth muscle cell (SMC)
phenotype causing medial wall calciﬁcation, suppression
of endogenous inhibitors of SMC calciﬁcation, stimulation
of SMC expression of alkaline phosphatase, and low bone
turnover leading to hyperphosphatemia and hypercalcemia
[14]. In the only prospective trial of CUA, the declining use
of calcium salts was associated with a decline in incidence
[18]. Chronic inﬂammatory states including autoimmune
disorders [19] and hypercoagulable states such as protein C
and protein S deﬁciency [20, 21] have also been identiﬁed
as potential contributors. Administration of certain medica-
tions including warfarin [22], systemic corticosteroids [23],
iron-dextran [24], erythropoietin [6], and albumin [25]h a s
been reported to be associated with calciphylaxis.
3.Diagnosis
Early recognition is the key to better treatment outcomes.
In lieu of any speciﬁc laboratory tests, the diagnosis is
most often clinical, made apparent by the presence of
proximal ulcers, intact peripheral pulses and the absence
of neuropathy in a patient with the above-mentioned risk
factors. The noninvasive tests including plain radiographs,
high-resolution computed tomography, bone scans, and X-
ray mammography are nonspeciﬁc for this condition. In
the absence of contraindications, the diagnosis may be
conﬁrmed by skin biopsy, which reveals calcifying septal
panniculitis and arterial occlusion and calciﬁcation in the
absence of vasculitic changes [26]. Skin biopsy may invite
further infection in the presence of an active infection, can
initiate ulcer formation and propagation, and is subject to
sampling error. Thus, it should be performed only after
considering and discussing the risks and beneﬁts of the
procedure with the patient.
4.Prognosis
Calciphylaxis continues to be a lethal complication with
an estimated one-year survival rate of 45.8 percent [23].
The presence of advanced disease at the time of therapy
and proximal ischemic lesions are poor prognostic features.
Ulceration carries a mortality of greater than 80 percent as a
result of local and systemic infections and sepsis [7].
5. Treatment Approach
The optimal therapy of calciphylaxis is to prevent its
development by rigorous control of phosphate and calcium
balance while avoiding or modifying the other risk factors.
Unfortunately, no randomized controlled trials are available
to guide management of aﬀected patients. A multidis-
ciplinary therapeutic approach is recommended in those
with established disease, focusing on local wound care and
metabolic control.
An aggressive local wound care program should be
initiated to prevent local and systemic infections [11]. This
typically involves the use of enzymatic debriding agents, wet-
to-dry dressings, hydrocolloid or hydrogel dressings, and
systemic antibiotics as needed for infections and avoidance
of local tissue trauma, including subcutaneous injections.
The role of surgical debridement for ulcerations in this
condition remains controversial [23]. Improved survival
rates have been documented; however, it predisposes the
patient to increased risk of sepsis and worsening pain. A
pain management specialist should be consulted to provide
adequate pain control anticipating a prolonged duration
of persistent discomfort. Emotional support should be
provided to the patient and family, as calciphylaxis is very
painful and debilitating disease. Nutritional status of the
patient should be well addressed. An increase in dietary
protein has been shown to promote wound healing in
patients with low serum protein [11].
Every eﬀort should be made to correct the underlying
abnormalities in plasma calcium andphosphorus concentra-
tions aiming for a target calcium and phosphorus product
below 55 and serum levels of phosphate between 2.7 and
4.6mg/dL [27]. A diet low in calcium and phosphate
should be strictly followed. Noncalcium-containing phos-
phate binders, such as sevelamer carbonate or lanthanum
carbonate, rather than calcium-based phosphate binders
should be administered as the latter increase the rate of
hypercalcemia [28]. Though no study has demonstrated
that the use of more frequent dialysis sessions or high-ﬂux
hemodialysis membranes alter the long-term outcome, the
dialysis dose should be increased in patients with inadequateInternational Journal of Nephrology 3
clearance [28]. A low-calcium-containing dialysis solution
(for both hemodialysis and peritoneal dialysis) may be
used to lower serum calcium levels [29], but their success
alone in healing the lesions remains unproven. Since the
activity of matrix Gla protein is dependent on vitamin K
carboxylation,discontinuationofwarfarintherapyshouldbe
strongly considered.
Normalization of serum parathyroid hormone (PTH)
levels should be attempted using cinacalcet rather than vita-
min D analogues, as the latter tends to raise the calcium and
phosphate product. Cinacalcet may serve as an alternative to
parathyroidectomy for the correction of secondary hyper-
parathyroidism [30]. However, parathyroidectomy should
still be considered for patients with refractory hyperparathy-
roidism. Parathyroidectomy has been shown to provide pain
relief and improve wound healing and short-term mortality,
yet the long-term beneﬁts are still unknown [5, 12, 31].
6. Novel Therapies
Sodium Thiosulfate. Sodium thiosulfate has been used ther-
apeutically for more than one hundred years for a variety of
conditions including acute cyanide poisoning, recurrent cal-
cium urolithiasis, nephrocalcinosis, and tumoral calcinosis.
Intravenous sodium thiosulfate has been increasingly used
as an adjunctive treatment in patients with debilitating cal-
ciphylactic necrotic lesions [32, 33]. Marked improvements
with reduction of pain and inﬂammation and improved
healing of ulcerative lesions have been demonstrated within
a few days to six months of use. The proposed mechanism of
action is that it dissolves insoluble calcium salts embedded
in tissue into soluble calcium thiosulfate. Other proposed
mechanisms include reversal of endothelial dysfunction and
increased vasodilatation through its antioxidant properties.
It is generally considered to be a safe and nontoxic drug.
Sulfate retention causing increased anion gap metabolic
acidosis has been occasionally reported with no documented
morbidityormortalityinhumansatthedosesusedclinically.
The reported doses vary from 5 to 25grams intravenously,
three to four times per week for a period of 6 to 24 months.
However, the optimum dosage schedule and duration of
treatment remains to be determined.
Bisphosphonates. Bisphosphonates have a powerful inhib-
itory eﬀect on osteoclast activity and bone resorption and
are largely used in treatment of osteoporosis, tumoral
hypercalcemia, and Paget’s disease. They have also been
shown to exert an inhibitory eﬀect on macrophage activity
and local proinﬂammatory cytokine production. Animal
models and few case reports have shown improvement of
calciphylaxis lesions associated with systemic inﬂammatory
response, when treated with intravenous pamidronate and
oral etidronate [34, 35]. This beneﬁt has been ascribed more
to their anti-inﬂammatory eﬀect than to their eﬀects on
calcium metabolism.
HyperbaricOxygenTherapy(HBO). HBOconsistsofbreath-
ing 100% oxygen at a pressure higher than ambient atmo-
spheric pressure (1 atmosphere absolute) while the patient
is situated inside a sealed treatment chamber. Healing is
impaired when tissue oxygen tension falls below 20mmHg.
Hypoxia also hinders with the oxygen-dependent poly-
morphonuclear leukocyte-mediated bacterial killing in the
wound infections. HBO therapy increases the amount of
oxygen in diseased tissue thereby promoting wound healing.
HBO at 2.5 atmospheres absolute has been used for 90
minutes, 5 days per week for 5 to 7 consecutive weeks in
reported cases. The therapy has been shown to be beneﬁcial
in healing cutaneous ulcers of calciphylaxis in some patients;
however, the treatments are costly and not readily available.
It may also increase the pain in some patients and remains
ineﬀective with organ involvement [36].
Steroids. The use of corticosteroids in the treatment of cal-
ciphylaxis remains controversial. In a single case report, the
use of prednisone resulted in stabilization or improvement
in nonulcerating lesions [7]; however, it may predispose
the patient to systemic infection [11]. Moreover, systemic
corticosteroids have even been reported to be a risk factor
for calciphylaxis in non-ESRD patients with an autoimmune
disorder [23].
Sterile Maggot Therapy. Larvae of the species Lucilia seri-
cata have been used to debride and disinfect skin lesions
of calciphylaxis. The maggots have enzymes that liquefy
necrotictissueandsecretephenylaceticacidandphenylacetyl
aldehyde, which have antibacterial activity that helps to
prevent infection [37]. This treatment is almost painless,
and results have been promising. The risks and long-term
outcomes still need to be assessed.
Anticoagulation Therapy. T h e r eh a v eb e e nc a s er e p o r t so f
use of low-dose tissue plasminogen activator [38]a n d
substitution of warfarin with low molecular weight heparin
[22] with proven beneﬁt in calciphylaxis.
Limb Revascularization. Limb revascularization has been
attempted to treat distal wound involvement, but gangrene
and lower-extremity ischemia continues to progress in
many patients, and the outcomes have been poor [39]. It
is debatable whether primary amputation should be the
treatment of lower-extremity calciphylaxis when ischemia is
also present.
Response to any therapy is assessed principally by
physical examination. The disease continues to have high
morbidityandmortalitywithpoorresponsetoanytherapeu-
tic regimen. Thus, early recognition and prompt initiation of
multidisciplinary treatment measures is vital.
7. Conclusions
Calciphylaxis is a severe form of metastatic calciﬁcation seen
in ESRD patients undergoing maintenance hemodialysis. It
often presents as ischemic skin ulceration and is associated
with high morbidity and mortality. Abnormal mineral
and bone metabolism is the strongest risk factor, and its
correction along with local wound care is the cornerstone4 International Journal of Nephrology
of the therapy. However, prevention is the best approach
as the outcomes remain poor despite many novel treatment
modalities.
Abbreviations
ESRD: End stage renal disease
CUA: Calciﬁc uremic arteriolopathy
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